Zantac and other heartburn drugs recalled over possible cancer link - CBS News

archive.today
webpage capture

Saved from

no other snapshots from this url |

26 Aug 2021 05:48:02 UTC

All snapshots | from host www.cbsnews.com
Webpage Screenshot
share download .zip report bug or abuse donate

- Afghanistan Turmoil
- Haiti Earthquake
- Free CBS News App
- Stream CBSN Live
- Sign Up For Newsletters
- COVID Pandemic
- CBS Village
- The Uplift

Watch CBSN Live

# Zantac and other heartburn drugs recalled over possible cancer link

April 1, 2020 / 4:24 PM / AP

CBSN Live

### Heartburn drug’s possible cancer link probe...

Jan 10, 2020
04:53

## Videos — Featured Playlist

### Heartburn drug’s possible cancer link probe...

Now Playing

### 1,500 Americans may still want to leave Afgha...

### 2013: A Long and Dangerous Journey

### Top U.S. diplomat in Afghanistan on evacuatio...

### Johnson & Johnson says its COVID booster shot...

### Public schools facing massive enrollment drop...

### Landlord faces homelessness amid eviction ban...

### Hazardous conditions from Caldor Fire threate...

### Paralympian on what representing the U.S. mea...

### Afghan evacuees taken to U.S. military base

Washington — U.S. health regulators are telling drugmakers to immediately pull their popular heartburn drugs off the market after determining that a contamination issue with the medications poses a greater risk than previously thought.
The move from the Food and Drug Administration Wednesday applies to all prescription and over-the-counter versions of ranitidine, best known by the brand name Zantac. The drugs are widely used to treat stomach acid and ulcers.
Patients should stop taking any of the medications they currently have and throw them away, the FDA said.

#### Sign up for Breaking News Alerts

Be in the know. Get the latest breaking news delivered straight to your inbox.
By signing up, you agree to the CBS Terms of Use and acknowledge the data practices in our Privacy Policy.
Receive updates, offers & other information from the CBS family of companies & our partners. Opt out through the unsubscribe link in any marketing email.
Thank you for subscribing
The agency last year said patients could continue taking the medications and did not face health risks from low levels of a "probable" cancer-causing contaminant found in multiple brands.
But officials reversed that decision, saying they've now determined that levels of the chemical increase over time, especially if tablets and capsules are stored at higher temperatures. That poses an unacceptable risk to patients, they said.
"Since we don't know how or for how long the product might have been stored, we decided that it should not be available to consumers and patients," said Dr. Janet Woodcock in a statement.
Woodcock said there are multiple alternative medications to treat heartburn, including Prilosec, Nexium and Tagament.
Many makers of ranitidine drugs already removed their products from the market, including Zantac-manufacturer Sanofi. Additionally several drug store chains pulled the drugs from their shelves last year.
Dozens of recalls have been linked to the same probable carcinogen since last year. The FDA is still investigating the issue and has sanctioned at least one manufacturing plant in India that makes ingredients used in the medications.
The FDA has suspended nearly all U.S. and foreign inspections due to travel restrictions caused by the coronavirus outbreak.

### Trending News

Landlord faces homelessness as tenants fall behind on rent
What's behind the push for a fourth stimulus check
Delta Air Lines to charge unvaccinated workers $200 a month
J&J says COVID-19 booster shot strengthens immunity

#### Sign up for Breaking News Alerts

Be in the know. Get the latest breaking news delivered straight to your inbox.
By signing up, you agree to the CBS Terms of Use and acknowledge the data practices in our Privacy Policy.
Receive updates, offers & other information from the CBS family of companies & our partners. Opt out through the unsubscribe link in any marketing email.
Thank you for subscribing
See All Newsletters

0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%